Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04657991
Title Encorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for V600E/K Positive Melanoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Pfizer
Indications

skin melanoma

Therapies

Pembrolizumab

Binimetinib + Encorafenib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST